Astrazeneca (AZN) Net Cash Flow (2009 - 2026)

Astrazeneca (AZN) has reported Net Cash Flow for 17 consecutive years, with -$1.5 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Cash Flow rose 61.49% year-over-year to -$1.5 billion; the TTM figure through Mar 2026 stood at -$11.9 billion (up 36.87% YoY), while the FY2025 annual figure was $4.4 billion, up 11.04% from the prior year.
• Net Cash Flow came in at -$1.5 billion for Q1 2026 at Astrazeneca, up from -$4.7 billion in the prior quarter.
• The five-year high for Net Cash Flow was -$385.0 million in Q1 2024, with the low at -$6.6 billion in Q4 2023.
• Average Net Cash Flow over 5 years is -$3.7 billion, with a median of -$4.0 billion recorded in 2025.
• Across the five-year window, Net Cash Flow soared 88.25% in 2024 and plunged 928.57% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at -$6.5 billion in 2022, then dropped by 1.58% to -$6.6 billion in 2023, then grew by 21.17% to -$5.2 billion in 2024, then advanced by 8.67% to -$4.7 billion in 2025, then jumped by 67.75% to -$1.5 billion in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$1.5 billion, -$4.7 billion, and -$4.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.